US FDA explains medtech benefit-risk evaluation and design considerations for pivotal trials
This article was originally published in Clinica
Executive Summary
The US Food and Drug Administration is seeking feedback on two draft guidance documents relating to the pre-market review of medical devices. The first guidance explains the factors the FDA considers when making benefit-risk determinations in pre-market reviews, and the second guidance sets out design considerations for pivotal clinical investigations.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.